ToxSci Advance Access originally published online on March 10, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Toxicological Sciences 79, 214-223 (2004)
Toxicological Sciences vol. 79 no. 2 © Society of Toxicology; all rights reserved.
REVIEW |
Use and Application of Stem Cells in Toxicology
* Pfizer, Inc., Pfizer Global Research and Development, St. Louis, Missouri 63167, and Groton, Connecticut 06340; University of Pittsburgh, Department of Pathology, Pittsburgh, Pennsylvania 15261; and Michigan State University, Department of Pediatric and Human Development, East Lansing, Michigan 48824
Received December 9, 2003; accepted February 15, 2004
ABSTRACT
In recent years, stem cells have been the subject of increasing scientific interest because of their utility in numerous biomedical applications. Stem cells are capable of renewing themselves; that is, they can be continuously cultured in an undifferentiated state, giving rise to more specialized cells of the human body such as heart, liver, bone marrow, blood vessel, pancreatic islet, and nerve cells. Therefore, stem cells are an important new tool for developing unique, in vitro model systems to test drugs and chemicals and a potential to predict or anticipate toxicity in humans. The following review provides an overview of the applications of stem cell technology in the area of toxicology. Specifically, this review addresses core technologies that are emerging in the field and how they could fulfill critical safety issues such as QT prolongation and hepatotoxicity, two leading causes of failures in preclinical development of new therapeutic drugs. We report how adult stem cells derived from various sources, such as human bone marrow and placenta, can potentially generate suitable models for cardiotoxicity, hepatotoxicity, genotoxicity/epigenetic and reproductive toxicology screens. Additionally, this review addresses the role and advantages of embryonic stem cells in the aforementioned models for toxicity and how genetic selection is employed to overcome major limitations to the implementation of stem cell-based in vitro models for toxicology.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Kim, E. Dere, L. D. Burgoon, C.-C. Chang, and T. R. Zacharewski Comparative Analysis of AhR-Mediated TCDD-Elicited Gene Expression in Human Liver Adult Stem Cells Toxicol. Sci., November 1, 2009; 112(1): 229 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Buesen, E. Genschow, B. Slawik, A. Visan, H. Spielmann, A. Luch, and A. Seiler Embryonic Stem Cell Test Remastered: Comparison between the Validated EST and the New Molecular FACS-EST for Assessing Developmental Toxicity In Vitro Toxicol. Sci., April 1, 2009; 108(2): 389 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shinozawa, A. Tsuji, K. Imahashi, K. Nakashima, H. Sawada, H. Toyoshiba, S. Yamamoto, K. Takami, and R. Imai Gene Expression Profiling of Functional Murine Embryonic Stem Cell-Derived Cardiomyocytes and Comparison with Adult Heart: Profiling of Murine ESC-Derived Cardiomyocytes J Biomol Screen, March 1, 2009; 14(3): 239 - 245. [Abstract] [PDF]
|
|
|
|
 |
|
 J. E. Trosko REVIEW PAPER: Cancer Stem Cells and Cancer Nonstem Cells: From Adult Stem Cells or from Reprogramming of Differentiated Somatic Cells Vet. Pathol., March 1, 2009; 46(2): 176 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Peters, M. Steemans, E. Hansen, N. Mesens, G. R. Verheyen, and P. Vanparys Evaluation of the Embryotoxic Potency of Compounds in a Newly Revised High Throughput Embryonic Stem Cell Test Toxicol. Sci., October 1, 2008; 105(2): 342 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shiraki, K. Umeda, N. Sakashita, M. Takeya, K. Kume, and S. Kume Differentiation of mouse and human embryonic stem cells into hepatic lineages. Genes Cells, July 1, 2008; 13(7): 731 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Norstrom, K. Akesson, T. Hardarson, L. Hamberger, P. Bjorquist, and P. Sartipy Molecular and Pharmacological Properties of Human Embryonic Stem Cell-Derived Cardiomyocytes Experimental Biology and Medicine, December 1, 2006; 231(11): 1753 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-K. Kim, B.-K. Kim, J.-H. Shim, J.-E. Gil, Y.-D. Yoon, and J.-H. Kim Nonylphenol and Octylphenol-Induced Apoptosis in Human Embryonic Stem Cells Is Related to Fas-Fas Ligand Pathway Toxicol. Sci., December 1, 2006; 94(2): 310 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Chaudhary, N. X. Barrezueta, M. B. Bauchmann, A. J. Milici, G. Beckius, D. B. Stedman, J. E. Hambor, W. L. Blake, J. D. McNeish, A. Bahinski, et al. Embryonic Stem Cells in Predictive Cardiotoxicity: Laser Capture Microscopy Enables Assay Development Toxicol. Sci., March 1, 2006; 90(1): 149 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. M. C. Zhang Protective Effect of Quercetin on Aroclor 1254-Induced Oxidative Damage in Cultured Chicken Spermatogonial Cells Toxicol. Sci., December 1, 2005; 88(2): 545 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Wobus and K. R. Boheler Embryonic Stem Cells: Prospects for Developmental Biology and Cell Therapy Physiol Rev, April 1, 2005; 85(2): 635 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Trosko and B. L. Upham The emperor wears no clothes in the field of carcinogen risk assessment: ignored concepts in cancer risk assessment Mutagenesis, March 1, 2005; 20(2): 81 - 92. [Abstract] [Full Text] [PDF]
|
|